Patient Reported Outcomes With LASIK: PROWL-2 (PROWL-2)
Patient-Reported Outcomes With LASIK: PROWL-2
Sponsor: Food and Drug Administration (FDA)
Listed as NCT01655420, this observational or N/A phase trial focuses on Laser in Situ Keratomileusis and remains completed. Sponsored by Food and Drug Administration (FDA), it has been updated 7 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Jul 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Food and Drug Administration (FDA)
- National Eye Institute (NEI)
For direct contact, visit the study record on ClinicalTrials.gov .